Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Says Government Investigations Must Be Avoided, Since "There Is No Way Of Winning" Once They Start

Executive Summary

Pfizer would like to avoid being in the government hot seat again. After paying the largest fine ever in a government investigation, the company has instituted procedures to prevent future problems with its marketing and sales practices

You may also be interested in...



Who Will Lead FDA In The Future? Succession Plan Is Not Enough, GAO Says

In its latest report card on FDA, the Government Accountability Office examines the agency's management of such challenges as recruiting and retaining its workforce and communicating with the public

Who Will Lead FDA In The Future? Succession Plan Is Not Enough, GAO Says

In its latest report card on FDA, the Government Accountability Office examines the agency's management of such challenges as recruiting and retaining its workforce and communicating with the public

Health Care Fraud Investigations Bedevil Pharma Industry: If You're Not Under Investigation, It's Only Because You've Recently Settled

Two months ago, the Department of Justice held a splashy news conference to announce its record-breaking $2.3 billion settlement with Pfizer. The event, which included HHS Secretary Kathleen Sebelius, cast a spotlight on Pfizer's alleged off-label marketing and kickbacks to health care providers (1"The Pink Sheet," Sept. 7, 2009)

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052015

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel